Erenumab

Erenumab
Monoclonal antibody
Type Whole antibody
Source Human
Target CGRPR
Clinical data
ATC code none
Legal status
Legal status
  • Investigational
Identifiers
CAS Number 1582205-90-0
ChemSpider none
Chemical and physical data
Formula C6472H9964N1728O2018S50
Molar mass 145.9 kDa

Erenumab (INN; developmental code name AMG-334) is a human monoclonal antibody against the calcitonin gene-related peptide receptor (CGRPR) designed for the prevention of migraine.[1][2][3]

This drug was developed by Amgen Inc.[3]

Clinical trials

In a Phase III clinical trial with 577 patients, the drug significantly reduced the number of migraine days per month by 3, versus 1.8 under placebo.[3]

References

  1. ↑ Statement On A Nonproprietary Name Adopted By The USAN Council - Erenumab, American Medical Association.
  2. ↑ World Health Organization (2016). "International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 115" (PDF). WHO Drug Information. 30 (2).
  3. 1 2 3 H. Spreitzer (24 October 2016). "Neue Wirkstoffe - Erenumab". Österreichische Apothekerzeitung (in German) (23/2016).


This article is issued from Wikipedia - version of the 12/1/2016. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.